Here are some interesting facts from the makers of the hsCRP assay:
C-reactive protein (CRP) is an acute phase protein that appears in circulation in response to inflammatory cytokines, such as interleukin-6, and serves as a biomarker for systemic inflammation. Following a systematic review of the association between inflammatory markers and coronary heart disease and stroke, the American Heart Association (AHA) and Centers for Disease Control and Prevention (CDC) developed a scientific statement that recommends hsCRP as a more sensitive assay for the prediction of vascular disease, compared to traditional assays for circulating C-reactive protein levels.
The AHA/CDC Scientific Statement Summary
- hsCRP is a global indicator of future vascular events in adults without any previous history of cardiovascular disease (CVD), with acceptable precision levels down to or below 0.3 mg/L
- hsCRP enhances risk assessment and therapeutic outcomes in primary CVD prevention
- hsCRP is particularly advantageous for assessing the risk in patients with
- Framingham 10-year risk scores of 10%-20% and/or
- LDL levels of <160>
- hsCRP acts as an independent marker for evaluating the possibility of recurrent cardiac events, such as myocardial infarction or restenosis, after percutaneous coronary intervention
|Average risk||1-3 mg/L|
|High risk||>3 mg/L|
Do you feel like you're an expert now? Click here to view the abstract for the JUPITER trial in the NEJM.